FDA in Flux: Navigating the New Regulatory Landscape

What do recent FDA policy changes mean for the pharmaceutical industry here at home? In this panel, we’ll dig into how these shifts are reshaping the regulatory landscape in the United States and what it means for companies operating domestically. From the challenges of balancing U.S. priorities with global harmonization efforts to the influence of geopolitics on domestic policy, this discussion will tackle the big questions. Our panelists will share real-world insights on navigating uncertainty, adapting to evolving regulations, and understanding the broader implications for pharmaceutical operations in the U.S. If you want to make sense of the changes happening in your own backyard, this is the conversation you need to hear.